| 0.824 -0.035 (-4.07%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.12  |
1-year : | 1.3 |
| Resists | First : | 0.95 |
Second : | 1.12 |
| Pivot price | 0.88  |
|||
| Supports | First : | 0.76 |
Second : | 0.65 |
| MAs | MA(5) : | 0.86 |
MA(20) : | 0.85 |
| MA(100) : | 0.87 |
MA(250) : | 0.84 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.2 |
D(3) : | 62.4 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 1.19 | Low : | 0.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BFRI ] has closed above bottom band by 6.9%. Bollinger Bands are 44.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.89 - 0.9 | 0.9 - 0.9 |
| Low: | 0.83 - 0.84 | 0.84 - 0.84 |
| Close: | 0.85 - 0.86 | 0.86 - 0.87 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Mon, 09 Mar 2026
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Yahoo Finance
Mon, 09 Mar 2026
Biofrontera reports positive Phase 2b Ameluz PDT results for moderate to severe acne - TradingView
Thu, 26 Feb 2026
Biofrontera (NASDAQ: BFRI) wins PTAB decision on Sun Pharma patent claims - Stock Titan
Thu, 26 Feb 2026
U.S. patent board backs Biofrontera in battle over Sun Pharma patent - Stock Titan
Tue, 17 Feb 2026
Biofrontera Inc. Announces Database Lock of Phase 1 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 8.17e+006 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 252 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.751e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -47.3 % |
| Operating Margin | -89.9 % |
| Return on Assets (ttm) | -65 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 3.716e+007 % |
| Gross Profit (p.s.) | -35.72 |
| Sales Per Share | 304.33 |
| EBITDA (p.s.) | 3.8e+007 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.36 |
| Dividend | 0 |
| Forward Dividend | 436860 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|